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Abstract
Background: There is an important need for the identification of novel serological biomarkers for the early
detection of cancer. Current biomarkers suffer from a lack of tissue specificity, rendering them vulnerable to non-
disease-specific increases. The present study details a strategy to rapidly identify tissue-specific proteins using
bioinformatics.
Methods: Previous studies have focused on either gene or protein expression databases for the identification of
candidates. We developed a strategy that mines six publicly available gene and protein databases for tissue-specific
proteins, selects proteins likely to enter the circulation, and integrates proteomic datasets enriched for the cancer
secretome to prioritize candidates for further verification and validation studies.
Results: Using colon, lung, pancreatic and prostate cancer as case examples, we identified 48 candidate tissue-
specific biomarkers, of which 14 have been previously studied as biomarkers of cancer or benign disease. Twenty-
six candidate biomarkers for these four cancer types are proposed.
Conclusions: We present a novel strategy using bioinformatics to identify tissue-specific proteins that are potential
cancer serum biomarkers. Investigation of the 26 candidates in disease states of the organs is warranted.
Keywords: bioinformatics, biomarkers, tissue-specific proteins
Background
Serological biomarkers represent a non-invasive and
cost-effective aid in the clinical management of cancer
patients, particularly in areas of disease detection, prog-
nosis, monitoring and therapeutic stratification. For a
serological biomarker to be useful for early detection, its
presence in serum must be relatively low in healthy
individuals and those with benign disease. The marker
must be produced by the tumor or its microenviron-
ment and enter the circulation, giving rise to increased
serum levels. Mechanisms that facilitate entry to the cir-
culation include secretion or shedding, angiogenesis,
invasion and destruction of tissue architecture [1]. The
biomarker should preferably be tissue specific, such that
a change in serum level can be directly attributed to dis-
ease (for example, cancer) of that tissue [2]. The cur-
rently most widely used serological biomarkers include
carcinoembryonic antigen (CEA) and carbohydrate anti-
gen 19.9 for gastrointestinal cancer [3-5]; CEA, cytoker-
atin 19 fragment, neuron-specific enolase, tissue
polypeptide antigen, progastrin-releasing peptide and
squamous cell carcinoma antigen for lung cancer [6];
CA 125 for ovarian cancer [2]; and prostate-specific
antigen (PSA, also known as kallikrein-related peptidase
(KLK) 3) in prostate cancer [7]. These current serologi-
cal biomarkers lack the appropriate sensitivity and speci-
ficity to be suitable for early cancer detection.
Serum PSA is commonly used for prostate cancer
screening in men over 50 years old, but its usage
remains controversial due to serum elevation in benign
disease as well as prostate cancer [8]. Nevertheless, PSA
represents one of the most useful serological markers
currently available. PSA is strongly expressed only in the
prostate tissue of healthy men, with low levels in the
serum established by normal diffusion through various
anatomical barriers. These anatomical barriers are dis-
rupted upon development of prostate cancer, allowing
increased amounts of PSA to enter circulation [1].
* Correspondence: ediamandis@mtsinai.on.ca
† Contributed equally
1Department of Laboratory Medicine and Pathobiology, University of
Toronto, Toronto, ON, Canada
Full list of author information is available at the end of the article
Prassas et al. BMC Medicine 2012, 10:39
http://www.biomedcentral.com/1741-7015/10/39
Clinical Biomarkers
© 2012 Prassas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Recent advances in high-throughput technologies (for
example, high-content microarray chips, serial analysis of
gene expression, expressed sequence tags) have enabled
the creation of publicly available gene and protein data-
bases that describe the expression of thousands of genes
and proteins in multiple tissues. In this study we used
five gene databases and one protein database. The C-It
[9,10], Tissue-specific and Gene Expression and Regula-
tion (TiGER) [11,12] and UniGene [13,14] databases are
based on expressed sequence tags (ESTs). The BioGPS
[15-17] and VeryGene [18,19] databases are based on
microarray data. The Human Protein Atlas (HPA)
[20,21] is based on immunohistochemistry (IHC) data.
Our laboratory has previously characterized the pro-
teomes of conditioned media (CM) from 44 cancer cell
lines, three near normal cell lines and 11 relevant biolo-
gical fluids (for example, pancreatic juice and ascites)
using multidimensional liquid chromatography tandem
mass spectrometry, identifying between 1,000 and 4,000
proteins per cancer site [22-33] (unpublished work).
Numerous candidate biomarkers have been identified
from in silico mining of gene-expression profiling
[34-36] and the HPA [37-48]. In the present study, we
describe a strategy to identify tissue-specific proteins
using publicly available gene and protein databases. Our
strategy mines databases for proteins highly specific to
or strongly expressed in one tissue, selects proteins
which are secreted or shed, and integrates proteomic
datasets enriched for the cancer secretome to prioritize
candidates for further verification and validation studies.
Integrating and comparing proteins identified from data-
bases based on different data sources (ESTs, microarray
and IHC) with the proteomes of the CM of cancer cell
lines and relevant biological fluids will minimize the
shortcomings of any one source, resulting in the identi-
fication of more promising candidates. Recently, the
value of using an integrated approach in biomarker dis-
covery has been described [49].
In this study, we looked at identifying tissue-specific
proteins as candidate biomarkers for colon, lung, pan-
creatic and prostate cancer. Our strategy can be applied
to identify tissue-specific proteins for other cancer sites.
Colon, lung, pancreatic and prostate cancer are ranked
among the top leading causes of cancer-related deaths,
cumulatively accounting for an estimated half of all can-
cer-related deaths [50]. Early diagnosis is essential for
improving patient outcomes as early-stage cancers are
less likely to have metastasized and are more amenable
to curative treatment. The five-year survival rate when
treatment is administered on metastatic stages com-
pared to organ-confined cancer drops dramatically from
91% to 11% in colorectal cancer, 53% to 4% in lung can-
cer, 22% to 2% in pancreatic cancer and 100% to 31% in
prostate cancer [50].
We identified 48 tissue-specific proteins as candidate
biomarkers for the selected tissue types. Of these, 14
had been previously studied as cancer or benign disease
serum biomarkers, providing credence to our strategy.
Investigation of the remaining proteins in future studies
is warranted.
Methods
In silico discovery
Six gene and protein databases were mined to identify
proteins highly specific to or strongly expressed in one
tissue. Colon, lung, pancreatic and prostate tissues were
examined.
The C-It database [10] was searched for each tissue
for proteins enriched in that selected tissue (human data
only). Since the C-It database did not have colon data
available, only lung, pancreatic and prostate tissue were
searched. Literature information search parameters of
fewer than five publications in PubMed and fewer than
three publications with the Medical Subject Headings
(MeSH) term of the searched tissue were used. The
option of adding z-scores of the corresponding SymA-
tlas microarray probe sets to the protein list was
included [16]. Only proteins with a corresponding
SymAtlas z-score of ≥|1.96|, corresponding to a 95%
confidence level of enrichment, were included in our
lists. Proteins without a SymAtlas z-score were ignored.
The TiGER database [12] was searched for proteins pre-
ferentially expressed in each tissue based on ESTs by
searching each tissue using ‘Tissue View’. The UniGene
database [14] was searched for tissue-restricted genes
using the following search criteria: [tissue][restricted] +
“Homo sapiens“, for the lung, pancreatic and prostate
tissues. Since the UniGene database did not have data
for colon tissue, a search of: [colorectal tumor]
[restricted] + “Homo sapiens“ was used.
The BioGPS database (v. 2.0.4.9037; [17]) plugin ‘Gene
expression/activity chart’ using the default human data
set ‘GeneAtlas U133A, gcrma’ [16] was searched with a
protein whose gene expression profile using the BioGPS
plugin showed it to be specific to and strongly expressed
in one tissue of interest. Chloride channel accessory 4,
surfactant protein A2, pancreatic lipase (PNLIP) and
KLK3 were selected for colon, lung, pancreatic and
prostate tissues, respectively. For each protein searched,
a correlation cutoff of 0.9 was used to generate a list of
proteins with a similar expression pattern to the initial
protein searched. Each tissue was searched in the Very-
Gene database [19] using ‘Tissue View’ for tissue-selec-
tive proteins.
The HPA [21] was searched for proteins strongly
expressed in each normal tissue with annotated expres-
sion. Annotated protein expression is a manually
curated score based on IHC staining patterns in normal
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different epitopes of the same protein, which describes
the distribution and strength of expression of each pro-
tein in cells [51].
Identification of protein overlap in databases
An in-house developed Microsoft Excel macro was uti-
lized to evaluate the number of times a protein was
identified in each tissue and which database had identi-
fied it. Proteins identified in only one database were
eliminated. Proteins identified in two or more databases
could represent candidates that are more promising at
this stage, since databases based on varying sources of
data identified the protein as being highly specific to or
strongly expressed in one tissue.
Secreted or shed proteins
For each tissue type, the list of proteins identified in two
or more databases was exported into a comma-delimited
Microsoft Excel file. An in-house secretome algorithm
(GS Karagiannis et al., unpublished work) was applied
to identify proteins that are either secreted or shed. The
secretome algorithm designates a protein as secreted or
shed if it is either predicted to be secreted based on the
presence of a signal peptide or through non-classical
secretion pathways, or predicted to be a membranous
protein based on amino-acid sequences corresponding
to transmembrane helices. Proteins that were not desig-
nated as secreted or shed were eliminated.
Verification of in silico expression profiles
The BioGPS and HPA databases were used to manu-
ally verify the expression profiles of the proteins iden-
tified as being secreted or shed for strength and
specificity of expression. The BioGPS database was
chosen above the other gene databases as it offers a
gene expression chart and the ability to batch search
for a list of proteins, which allowed efficient searching
and verification of protein lists. If expression profiles
were not available in the BioGPS database, the protein
was eliminated.
The BioGPS database plugin ‘Gene expression/activity
chart’ using the default human data set ‘GeneAtlas
U133A, gcrma’ was searched for each protein. For each
tissue, proteins with gene expression profiles showing
similar values of expression or strong expression in
more than the selected tissue were eliminated (strong
expression is defined as ≥ 10 times the median expres-
sion value in all tissues). In BioGPS, the color of the
bars in the ‘Gene expression/activity chart’ reflects a
grouping of similar samples, based on global hierarchical
clustering. If strong expression was seen in more than
the selected tissue, but only in tissues with the same bar
color, the protein was not eliminated.
The HPA was searched for each protein, and the ‘Nor-
mal Tissue’ expression page was evaluated. Tissue pre-
sentation order by organ was selected. An evaluation of
the protein’s expression in normal tissue was preferably
based on the level of annotated protein expression or, if
the annotated expression was not available, the level of
antibody staining. The levels of annotated protein
expression are none, low, medium and high and the
levels of antibody staining are negative, weak, moderate
and strong. For each tissue, proteins with high/strong
expression in the selected tissue and medium/moderate
expression in more than two other tissues were elimi-
nated. Proteins with high/strong or medium/moderate
expression in more than the one selected tissue were
eliminated. Proteins with low/weak or none/negative
expression in the selected tissue were eliminated. If the
high/strong or the medium/moderate level was seen in
more than the one selected tissue, where the other tis-
sues were in the same organ, and low/weak or none/
negative expression was seen in all other tissues, the
protein was included.
Proteins with pending HPA data were evaluated based
on their gene expression profiles. Proteins were also
eliminated when their HPA protein expression profiles
fit the criteria for elimination but their gene expression
profiles did not fit the criteria for elimination.
Literature search
The PubMed database was manually searched for each
of the proteins whose expression profile was verified in
silico. For each tissue, proteins that had been previously
studied as candidate cancer or benign disease serum
biomarkers in the selected tissue were eliminated. Pro-
teins with high abundance in serum ( > 5 μg/mL) or
known physiology and expression were also eliminated.
Proteomic datasets
An in-house Microsoft Excel macro was utilized for
comparison of the remaining protein lists against pre-
viously characterized in-house proteomes of the CM
from 44 cancer cell lines, three near normal cell lines
and 11 relevant biological fluids [22-33] (unpublished
work). Proteomes were characterized using multidimen-
sional liquid chromatography tandem mass spectrometry
on a linear ion trap (LTQ) Orbitrap mass spectrometer
(Thermo Fisher Corporation, Pittsburgh, PA, USA). For
details, see our previous publications [22-33]. The can-
cer cell lines were from six cancer types (breast, colon,
lung, ovarian, pancreatic and prostate). The relevant bio-
logical fluids included amniotic fluid (normal, with
Down Syndrome), nipple aspirate fluid, non-malignant
peritoneal fluid, ovarian ascites, pancreatic ascites, pan-
creatic juice, pancreatic tissue (normal and malignant)
and seminal plasma. A complete list of cell lines and
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If a protein was identified in amniotic fluid and the pro-
teome of a tissue, this was noted but not considered as
expression in a non-tissue proteome.
T h ed a t ao fp r o t e o m e sf r o mt h eC Mo f2 3c a n c e rc e l l
lines (from 11 cancer types), as recently published by
Wu et al. [52], was also integrated. Proteomes were
characterized using one-dimensional SDS-PAGE and
nano-liquid chromatography tandem mass spectrometry
on a LTQ-Orbitrap mass spectrometer. The 11 cancer
types included breast, bladder, cervical, colorectal, epi-
dermoid, liver, lung, nasopharyngeal, oral and pancreatic
cancer, and T-cell lymphoma [52]. If a protein was iden-
tified in a proteomic dataset, the proteome in which it
was identified was noted.
A schematic outline of the methodology is provided in
Figure 1.
Results
Identification of proteins
A total of 3,615 proteins highly specific to or strongly
expressed in the colon, lung, pancreas or prostate were
identified in the databases. Searching the databases iden-
tified 976 unique proteins that were highly specific to or
strongly expressed in the colon, 679 for the lung, 1,059
for the pancreas and 623 for the prostate (Table 1). For
the four tissue types, the C-It database identified 254 tis-
sue-enriched proteins, the TiGER database identified
636 proteins preferentially expressed in tissue and the
UniGene database identified 84 tissue-restricted pro-
teins. The BioGPS database identified 127 proteins simi-
larly expressed as a protein with known tissue
specificity, and the VeryGene database identified 365
tissue-selective proteins. The HPA identified 2,149 pro-
teins showing strong tissue staining and with annotated
expression. The total number of proteins identified by
each database in the four tissue types contains some
proteins that were identified in more than one tissue. A
complete list of proteins identified in each tissue by
each database is presented in Additional file 2 and is
summarized in Additional file 3.
Protein identification overlap in databases
A total of 32 proteins in the colon, 36 proteins in the
lung, 81 proteins in the pancreas and 48 proteins in the
prostate were identified in two or more databases.
Selecting for proteins identified in two or more data-
bases eliminated between 92% and 97% of the proteins
in each of the tissue types. The majority of the remain-
ing proteins were identified in only two of the databases,
and no proteins were identified in all the databases. This
data is summarized in Table 1 and a complete list of
proteins identified in one or more databases, including
the number of databases it was identified in and which
databases those were, is presented in Additional file 4
for each tissue.
Secreted or shed proteins
The majority of the proteins identified in two or more
databases were identified as being secreted or shed. In
total, 143 of the 197 proteins from all tissues were
designated as being secretedo rs h e d( T a b l e1 ) .S p e c i f i -
cally, 26 proteins in the colon, 25 proteins in the lung,
58 proteins in the pancreas and 34 proteins in the pros-
tate were designated as being secreted or shed. A com-
plete list is provided in Additional file 5.
Figure 1 Schematic outline of tissue-specific biomarker identification. Protein identification in six publicly available gene and protein
databases, grouped by the type of data each database is based on, followed by filtering criteria and integration of proteomic datasets to
identify and prioritize candidates is outlined. ESTs: expressed sequence tags; HPA: Human Protein Atlas; IHC: immunohistochemistry; TiGER:
Tissue-specific and Gene Expression and Regulation.
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Manual verification of the expression profiles of the
secreted or shed proteins identified in two or more
databases eliminated the majority of the proteins: 21 in
t h ec o l o n ,1 6i nt h el u n g ,3 2i nt h ep a n c r e a sa n d2 6i n
the prostate. Only five (0.5%) of the 976 proteins initially
identified as highly specific to or strongly expressed in
the colon were found to meet the filtering criteria. Nine
(1.3%) of 679 proteins in the lung, 26 (2.4%) of 1,059
proteins in the pancreas and eight (1.3%) of 623 proteins
in the prostate were found to meet the filtering criteria.
These remaining 48 proteins are tissue-specific and
secreted or shed and, therefore, represent candidate bio-
markers (Table 2).
Performance of databases
The performance of the databases was evaluated by
determining how many of the 48 proteins that passed
the filtering criteria were initially identified by each
database (Figure 2). The TiGER database had been
responsible for initially identifying the greatest number
of proteins that passed the filtering criteria. The TiGER
database, the BioGPS database and the VeryGene data-
base had each identified > 68% of the 48 proteins. The
TiGER database had identified 40 of the 48 proteins,
and the BioGPS and VeryGene databases had both iden-
tified 33 of 48 proteins. The UniGene database identi-
fied 35% (17 out of 48) of the proteins and the C-It
database and the HPA both identified 19% (9 out of 48)
of the proteins (Table 2).
The accuracy of the initial protein identifications was
evaluated by comparing the proportion of proteins that
had passed the filtering criteria that each database had
initially identified to the total number of proteins each
database initially identified. The BioGPS database
showed the highest accuracy of initial protein identifica-
tion. Of the proteins initially identified by the BioGPS
database, 26% (33 of 127) met all the filtering criteria.
The UniGene database showed 20% accuracy (17 of 84),
V e r y G e n es h o w e d9 %( 3 3o f3 6 5 ) ,T i G E Rs h o w e d6 %
(40 of 636), C-It showed 4% (9 of 254) and HPA showed
0.4% (9 of 2,149).
Literature search
None of the colon-specific proteins had been previously
studied as serum colon cancer biomarkers. Surfactant
proteins have been extensively studied in relation to var-
ious lung diseases [53], and surfactant protein A2, sur-
factant protein B and surfactant protein D have been
studied as serum lung cancer or lung disease biomarkers
[54-56]. Elastase proteins have been studied in pancrea-
tic function and disease [57], islet amyloid polypeptide
and pancreatic polypeptide are normally secreted
[58,59], and glucagon and insulin are involved in the
normal function of healthy individuals. Eight of the pan-
creas-specific proteins had been previously studied as
serum pancreatic cancer or pancreatitis biomarkers
[33,60-65]. Four of the prostate-specific proteins had
been previously studied as serum prostate cancer bio-
markers [66-68] (Table 2).
Protein overlap with proteomic datasets
Of the tissue-specific proteins that had not been studied
as serum tissue cancer biomarkers, 18 of the 26 proteins
were identified in proteomic datasets (Tables 3, 4, 5 and
6). Nine proteins were exclusively identified in datasets
of corresponding tissues. Of the colon-specific proteins,
only glycoprotein A33 (GPA33) was identified exclu-
sively in colon datasets. GPA33 was identified in the
CM of three colon cancer cell lines, LS174T, LS180 and
Colo205 [52] (GS Karagiannis et al., unpublished work)
(Table 3). None of the lung-specific proteins were iden-
tified in lung datasets (Table 4). Seven pancreas-specific
proteins were exclusively identified in pancreatic data-
sets: in pancreatic cancer ascites [32], pancreatic juice
[33] and normal or cancerous pancreatic tissue
Table 1 Total number of proteins identified from mining gene and protein databases
Tissue
Colon Lung Pancreas Prostate
Total unique proteins 976 679 1059 623
[in ≥ two databases] [32] [36] [81] [48]
Number of proteins identified in
One database 944 643 968 575
Two databases 23 30 46 32
Three databases 7 5 23 11
Four databases 1 1 9 4
Five databases 1 - 3 1
Number [%] of secreted or shed
proteins in ≥ two databases
a
26
[81]
25
[69]
58
[72]
34
[71]
aPertains to proteins identified using a secretome algorithm
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Page 5 of 13Table 2 Forty-eight proteins identified as tissue-specific, strongly expressed and secreted or shed in colon, lung,
pancreatic or prostate tissue
a
Tissue Gene BioGPS
[15,16]
C-It
[9]
HPA
[20]
TiGER
[11]
UniGene
[13]
VeryGene
[18]
Previously studied as a (tissue) cancer or benign disease
serum biomarker [reference]
Colon CEACAM7 √√
CLCA1 √√ √
GPA33 √√
LEFTY1 √√
ZG16 √√
Lung IRX5 √√ √
LAMP3 √√
MFAP4 √√
SCGB1A1 √√ √
SFTPA2 √√ [54-56]
SFTPB √√ √ [55]
SFTPC √√
SFTPD √√ √ [56]
TMEM100 √√ √
Pancreas AQP8 √√
CEL √√ √ [60]
CELA2A √√ [61]
CELA2B √√ √ √
CELA3B √√
CPA1 √√ √ √ √ [62]
CPA2 √√ √ √ [62]
CPB1 √√ √ √ [63]
CTRB1 √√
CTRB2 √√ √
CTRC √√ √
CUZD1 √√ √
GCG √√ √
IAPP √√ √
INS √√ √
KLK1 √√ √
PNLIP √√ √ √ [64]
PNLIPRP1 √√ √
PNLIPRP2 √√ √
PPY √√ √
PRSS1 √√ √ √ √ [65]
PRSS3 √√
REG1B √√ √
REG3G √√ √
SLC30A8 √√ √
SYCN √√ √ √ √[33]
Prostate ACPP √√ √ √ √ [66]
FOLH1 √√ [67]
KLK2 √√ [68]
KLK3 √√ √ [66]
NPY √√
PSCA √√
RLN1 √√ √ √
SLC45A3 √√ √ √
aTissue-specific proteins as it applies to this table indicates protein expression was manually verified in BioGPS and/or HPA databases. HPA: Human Protein Atlas;
TiGER: Tissue-specific and Gene Expression and Regulation.
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were identified in the CM of pancreatic cancer cell
lines. Neuropeptide Y (NPY) was the only prostate-spe-
cific protein identified exclusively in prostate datasets.
NPY was identified in the CM of the prostate cancer
c e l ll i n eV C a P( PS a r a o net al.,u n p u b l i s h e dw o r k )a n d
the seminal plasma proteome [25].
Discussion
We describe a strategy to identify tissue-specific biomar-
kers using publicly available gene and protein databases.
Since serological biomarkers are protein-based, using
only protein expression databases for the initial identifi-
cation of candidate biomarkers seems more relevant.
While the HPA has characterized more than 50% of
human protein-encoding genes (11,200 unique proteins
to date), it has not completely characterized the pro-
teome [51]. Therefore, proteins that have not been char-
acterized by the HPA but fulfill our desired criteria
would be missed by searching only the HPA. There are
also important limitations in using gene expression data-
bases since there is considerable variation between
mRNA and protein expression [69,70] and gene
expression does not account for post-translational modi-
fication events [71]. Therefore, mining both gene and
protein expression databases minimizes the limitations
of each platform. To the best of our knowledge, no stu-
dies for the initial identification of candidate cancer bio-
markers have been conducted using both gene and
protein databases.
Initially, the databases were searched for proteins
highly specific to or strongly expressed in one tissue.
The search criteria were tailored to accommodate the
design of the databases, which did not allow for simulta-
neous searching with both criteria. Identifying proteins
that were highly specific to and strongly expressed in
one tissue was considered in a later step. In the verifica-
tion of the expression profiles (see Methods), only 34%
(48 of 143) of the proteins were found to meet both cri-
teria. The number of databases mined in the initial iden-
tification can be varied at the discretion of the
investigator. Additional databases will result in the same
number of, or more, proteins being identified in two or
more databases.
In the gene expression databases, the criteria used
were set for maximum stringency for protein
Figure 2 Identification of tissue-specific proteins by each database. Venn diagrams depicting which database had initially identified the
tissue-specific proteins that passed the filtering criteria (identified in two or more databases, designated as secreted or shed, and expression
profiles verified in silico). Overlap of tissue-specific proteins identified in databases based off (a) ESTs, (b) microarray and (c) three databases that
identified the most tissue-specific proteins is also depicted. For details see text.
Table 3 List of colon tissue-specific proteins which have not been previously studied as serum cancer or benign
disease biomarkers
Gene Protein name Proteome identified in:
CM proteome from
colon cancer cell lines
Non-colon proteome
CEACAM7 Carcinoembryonic antigen-related
cell adhesion molecule 7
√ CM proteome from Hep 3B [52];
pancreatic juice proteome [33]
CLCA1 Chloride channel accessory 1 √ Normal, Down Syndrome amniotic fluid [22,23]
GPA33 Glycoprotein A33 √ LS174T
a, LS180
a, Colo205 [52]
LEFTY1 Left-right determination factor 1
ZG16 Zymogen granule protein 16 homolog (rat) √ CM proteome from Hep 3B [52]
aCM proteome of colon cancer cell lines (GS Karagiannis et al., unpublished work). CM: conditioned media.
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dates. A more exhaustive search can be conducted using
lower stringency criteria. The stringency could be varied
in the correlation analysis using the BioGPS database
plugin and the C-It database. The correlation cutoff of
0.9 used in identifying similarly expressed genes in the
BioGPS database plugin could be reduced to as low as
0.75. The SymAtlas z-score of ≥|1.96| could be reduced
to ≥|1.15|, corresponding to a 75% confidence level of
enrichment. The literature information parameters used
in the C-It database of fewer than five publications in
PubMed and fewer than three publications with the
MeSH term of the selected tissue could be reduced in
stringency, to allow identification of well-studied pro-
teins. Since C-It does not look at the content of publica-
tions in PubMed, it filters out proteins that have been
studied even if they have not been studied in relation to
cancer.
Although proteins that have been well studied but not
as cancer biomarkers represent potential candidates, the
emphasis in this study was on identifying novel candi-
dates which have been, overall, minimally studied. A
Table 4 List of lung tissue-specific proteins which have not been previously studied as serum cancer or benign disease
biomarkers
Gene Protein name Proteome identified in:
CM proteome from lung
cancer cell lines [27,52]
Non-lung proteome
IRX5 Iroquois homeobox 5
LAMP3 Lysosomal-associated membrane protein 3
MFAP4 Microfibrillar-associated protein 4 √ Normal and cancer pancreatic tissue
a, seminal
plasma proteome [25]; non-malignant peritoneal fluid [26]
SCGB1A1 Secretoglobin, family 1A, member 1 (uteroglobin) √ [22,23,25,26,31-33]
TMEM100 Transmembrane protein 100
aProteome of normal and cancer pancreatic tissue (H Kosanam et al., unpublished work). CM: conditioned media.
Table 5 List of pancreas tissue-specific proteins which have not been previously studied as serum cancer or benign
disease biomarkers
Gene Protein name Proteome identified in:
CM proteome from
pancreatic cancer cell
lines [33]
Pancreatic cancer
ascites proteome
[32]
Pancreatic
juice
proteome [33]
Pancreatic
tissue
a
Non-pancreas
proteome
Normal Cancer
AQP8 Aquaporin 8
CTRB1 Chymotrypsinogen B1 √√ Down Syndrome
amniotic fluid [22]
CTRB2 Chymotrypsinogen B2 √√
CTRC Chymotrypsin C
(caldecrin)
√√ √
CUZD1 CUB and zona pellucida-
like domains 1
√√
KLK1 Kallikrein 1 √√ √
PNLIPRP1 Pancreatic lipase-related
protein 1
√√
PNLIPRP2 Pancreatic lipase-related
protein 2
√√ √ CM proteome from
Hep 3B [52]
PRSS3 Protease, serine, 3 √√ √ √ √ HCC-38
b; HCC-1143
b;
normal amniotic fluid
[23]
REG1B Regenerating islet-
derived 1 beta
√√ √
REG3G Regenerating islet-
derived 3 gamma
√√ Seminal plasma
proteome [25]
SLC30A8 Solute carrier family 30
(zinc transporter),
member 8
aProteome of normal and cancer pancreatic tissue (H Kosanam et al., unpublished work);
bCM proteome of breast cancer cell lines (M Pavlou et al., unpublished
work). CM: conditioned media.
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Page 8 of 13gene’s mRNA level and protein expression can have sig-
nificant variability. Therefore, if lower stringency criteria
were used when identifying proteins from gene expres-
sion databases, a greater number of proteins would have
been identified in at least two of the databases, poten-
tially leading to a greater number of candidate protein
biomarkers identified after application of the remaining
filtering criteria.
The HPA was searched for proteins strongly expressed
in one normal tissue with annotated IHC expression.
Annotated IHC expression was selected because it uses
paired antibodies to validate the staining pattern, pro-
viding the most reliable estimation of protein expres-
sion. Approximately 2,020 of the 10,100 proteins in
version 7.0 of the HPA have annotated protein expres-
sion [51]. Makawita et al. [33] included the criteria of
annotated protein expression when searching for pro-
teins with ‘strong’ pancreatic exocrine cell staining for
prioritization of pancreatic cancer biomarkers. A more
exhaustive search could be conducted by searching the
HPA without annotated IHC expression.
Secreted or shed proteins have the highest chance of
entering the circulation and being detected in the
serum. Many groups, including ours [23-25,27-33], use
Gene Ontology [72] protein cellular localization annota-
tions of ‘extracellular space’ and ‘plasma membrane’ to
identify a protein as secreted or shed. Gene Ontology
cellular annotations do not completely describe all pro-
teins and are not always consistent if a protein is
secreted or shed. An in-house secretome algorithm (GS
Karagiannis et al., unpublished work) designates a pro-
tein as secreted or shed if it is predicted either to be
secreted based on the presence of signal peptide or to
have non-classical secretion, or predicted to be a mem-
branous protein based on amino-acid sequences corre-
sponding to transmembrane helices. It more robustly
d e f i n e sp r o t e i n sa ss e c r e t e do rs h e da n dw a st h e r e f o r e
used in this study.
Evaluating which of the databases had initially identi-
fied the 48 tissue-specific proteins that passed the
filtering criteria showed that the gene expression data-
bases had identified more of the proteins than the pro-
tein expression database. The HPA had initially
identified only 9 of the 48 tissue-specific proteins. The
low initial identification of tissue-specific proteins was
due to the stringent search criteria requiring annotated
IHC expression. For example, 20 of the 48 tissue-speci-
fic proteins had protein expression data available in the
HPA, of which the 11 proteins that were not initially
identified by HPA did not have annotated IHC expres-
sion. The expression profiles of those proteins would
have passed the ‘Verification of in silico expression pro-
files’ filtering criteria and, therefore, would have resulted
in a greater initial identification of tissue-specific pro-
teins by the HPA.
The HPA has characterized 11,200 unique proteins,
which is more than 50% of the human protein-encoding
genes [51]. Of the 48 tissue-specific proteins that met
the selection criteria, only nine were initially identified
from mining the HPA. Twenty of the tissue-specific pro-
teins have been characterized by the HPA. This demon-
strates the importance of combining gene and protein
databases to identify candidate cancer serum biomar-
kers. If only the HPA had been searched for tissue-spe-
cific proteins, even with lowered stringency, the 28
proteins that met the filtering criteria and represent can-
didate biomarkers would not have been identified.
The TiGER, UniGene and C-It databases are based on
ESTs and collectively identified 46 of the 48 proteins.
Of those, only 41% (19 of the 46) were identified in two
or more of those databases. The BioGPS and VeryGene
databases are based on microarray data and collectively
identified 46 of the 48 proteins. Of those, 56% (26 of
the 46) were identified uniquely by BioGPS and Very-
Gene. Clearly, even though databases are based on simi-
lar sources of data, individual databases still identified
unique proteins. This demonstrates the validity of our
initial approach of using databases that differently mine
t h es a m ed a t as o u r c e .T h eT i G E R ,B i o G P Sa n dV e r y -
Gene databases collectively identified all 48 of the
Table 6 List of prostate-specific proteins which have not been previously studied as serum cancer or benign disease
biomarkers
Gene Protein name Proteome identified in:
CM proteome from
prostate cancer cell lines
Seminal plasma
proteome[25]
Non-prostate proteome
NPY Neuropeptide Y √ VCaP
a √
PSCA Prostate stem cell
antigen
√ PC3 [28] √√ Normal and cancer pancreatic tissue
b; CM proteome from
pancreatic cancer cell lines SU.86.86, CAPAN1 [33]
RLN1 Relaxin 1
SLC45A3 Solute carrier family
45, member 3
aCM proteome from prostate cancer cell line (P Saraon et al., unpublished work);
bproteome of normal and cancer pancreatic tissue (H Kosanam et al.,
unpublished work). CM: conditioned media.
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Page 9 of 13tissue-specific proteins. From those three databases, 88%
(42 of the 48) were identified in two or more databases,
demonstrating the validity of selecting proteins identi-
fied in more than one database.
The accuracy of the databases’ initial protein identifi-
cation is related to how explicitly the database could be
searched for the filtering criteria of proteins highly spe-
cific to and strongly expressed in one tissue. The
BioGPS database had the highest accuracy at 26%, as it
was searched for proteins similarly expressed as a pro-
tein of known tissue specificity and strong expression.
The UniGene database, with an accuracy of 20%, could
only be searched for proteins with tissue-restricted
expression, without the ability to search for proteins
also with strong expression in the tissue. The VeryGene
database, accuracy of 9%, was searched for tissue-selec-
tive proteins and the TiGER database, with 6% accuracy,
was searched for proteins preferentially expressed in a
tissue. Their lower accuracies reflect that they could not
be explicitly searched for proteins highly specific to only
one tissue. The C-It database, with an accuracy of 4%,
searched for tissue-enriched proteins and the HPA,
accuracy of 0.4%, searched for proteins with strong tis-
sue staining. These very low accuracies reflect that the
search looked for proteins with strong expression in a
tissue, but could not be searched for proteins highly
specific to only one tissue.
The low identification of tissue-specific proteins by
the C-It database is not unexpected. Given that the lit-
erature search parameters initially used filtered out any
proteins that had fewer than five publications in
PubMed, regardless of whether those publications were
related to cancer, C-It only identified proteins enriched
in a selected tissue which have been minimally, if at all,
studied. Of the nine proteins C-It initially identified
from the tissue-specific list, eight of the proteins had
not been previously studied as serum candidate cancer
biomarkers. Syncollin (SYCN) has only very recently
been shown to be elevated in the serum of pancreatic
cancer patients [33]. The eight remaining proteins that
C-It identified represent especially interesting candidate
biomarkers because they represent proteins that fulfill
the filtering criteria but have not been well studied.
A PubMed search revealed that 15 of the 48 tissue-
specific proteins identified had been previously studied
as serum markers of cancer or benign disease, providing
credence to our approach. The most widely used bio-
markers currently suffer from a lack of sensitivity and
specificity due to the fact they are not tissue-specific.
CEA is a widely used colon and lung cancer biomarker.
It was identified by the BioGPS and TiGER databases
a n dt h eH P Aa sh i g h l ys p e c i f i ct oo rs t r o n g l ye x p r e s s e d
in the colon, but not by any of the databases for the
lung. CEA was eliminated upon evaluating the protein
expression profile in silico, because it is not tissue speci-
fic. High levels of CEA protein expression were seen in
the normal tissues of the digestive tract, such as the eso-
phagus, small intestine, appendix, colon and rectum, as
well as in bone marrow, and medium levels were seen
in the tonsil, nasopharynx, lung and vagina. PSA is an
established, clinically relevant biomarker for prostate
cancer with demonstrated tissue specificity. PSA was
identified in our strategy as a prostate-specific protein,
after passing all the filtering criteria. This provides cre-
dence to our approach becausew er e - i d e n t i f i e dk n o w n
clinical biomarkers and our strategy filtered out the bio-
markers based on tissue specificity.
From the list of candidate proteins that have not been
studied as serum cancer or benign disease biomarkers,
18 of the 26 proteins were identified in proteomic data-
sets. The proteomic datasets primarily contain the CM
proteomes of various cancer cell lines, and other rele-
vant fluids, enriched for the secretome. For proteins that
have not been characterized by the HPA, it is possible
the transcripts are not translated, in which case they
would represent unviable candidates. If the transcripts
are translated and the protein enters circulation, it must
do so at a level detectable by current proteomic techni-
ques. Proteins that have been characterized by the HPA
may not necessarily enter the circulation. The identifica-
tion of a protein in the proteomic datasets verifies the
presence of the protein in the secretome of cancer at a
detectable level; therefore, the protein represents a
viable candidate. Because cancer is a highly heteroge-
neous disease, the integration of multiple cancer cell
lines and relevant biological fluids likely provides a
more, if not necessarily complete picture of the cancer
proteome.
Relaxin 1 is a candidate protein that was not identified
in any of the proteomes but its expression was con-
firmed by semi-quantitative RT-PCR in prostate carcino-
mas [73]. Therefore, a protein not being identified in
any of the proteomic datasets does not necessarily imply
that it is not expressed in cancer.
Acid phosphatase is a previously studied prostate can-
cer serum biomarker [74]. When compared to proteo-
mic datasets (data not shown), it was identified in the
seminal plasma proteome [25], the CM of many prostate
cancer cell lines [28] (P Saraon et al., unpublished work)
and, interestingly, the CM of colon cancer cell lines
Colo205 [52] and LS180 (GS Karagiannis et al.,u n p u b -
lished work), the CM of breast cancer cell lines HCC-
1143 (MP Pavlou et al., unpublished work) and MCF-7
[52], the CM of oral cancer cell line OEC-M1 [52] and
the CM of ovarian cancer cell line HTB161 (N Musrap
et al., unpublished work). Graddis et al. [74] observed
very low levels of acid phosphatase mRNA expression in
both normal and cancerous breast and colon tissue, in
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Page 10 of 13normal ovary and salivary gland tissue and compara-
tively high levels in normal and malignant prostate tis-
sue. We, therefore, reasoned that identification of a
tissue-specific protein in a proteome of a different tissue
does not necessarily correlate with strong expression in
that proteome.
Identification of a tissue-specific protein in only pro-
teomes corresponding to that tissue, coupled with in
silico evidence of strong and specific protein expression
in that tissue, indicates an especially promising candidate
cancer biomarker. SYCN has been shown to be increased
in the serum of pancreatic cancer patients [33]. SYCN
was identified in the pancreatic juice proteome [33] and
in normal pancreatic tissue (H Kosanam et al.,u n p u b -
lished work) and by BioGPS, C-It, TiGER, UniGene and
VeryGene databases as strongly expressed in only the
pancreas. Folate hydrolase 1, also known as prostate-spe-
cific membrane antigen, and KLK2 have been studied as
prostate cancer serum biomarkers [67,68]. Folate hydro-
lase 1 and KLK2 were both identified in the CM of var-
ious prostate cancer cell lines [28] (P Saraon et al.,
unpublished work) and the seminal plasma proteome
[25] and by BioGPS and TiGER databases as strongly
expressed in only the prostate. Of the tissue-specific pro-
teins which have not been previously studied as serum
cancer or benign disease biomarkers, colon-specific pro-
tein GPA33, pancreas-specific proteins chymotrypsino-
gen B1 and B2, chymotrypsin C, CUB and zona
pellucida-like domains 1, KLK1, PNLIP-related protein 1
and 2, regenerating islet-derived 1 beta and 3 gamma and
prostate-specific protein NPY represent such candidates.
Investigation of these candidates should be prioritized for
further verification and validation studies.
The proposed strategy seeks to identify candidate tis-
sue-specific biomarkers for further experimental studies.
Using colon, lung, pancreatic and prostate cancer as
case examples, we identified a total of 26 tissue-specific
candidate biomarkers. In the future, we intend to vali-
date the candidates; if validation is successful, we can
validate the use of this strategy for in silico cancer bio-
marker discovery. Using this strategy, investigators can
rapidly screen for candidate tissue-specific serum bio-
markers and prioritize candidates for further study
based on overlap with proteomic datasets. This strategy
can be used to identify candidate biomarkers for any tis-
sue, contingent on the data availability in the mined
databases, and incorporate various proteomic datasets at
the discretion of the investigator.
Conclusions
We present a novel strategy using bioinformatics to
identify tissue-specific proteins that are potential cancer
serum biomarkers. Investigation of the 26 candidates in
disease states of the organs is warranted.
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